Extract from the Register of European Patents

EP About this file: EP3125904

EP3125904 - AUTOIMMUNITY AND MULTIPLE SCLEROSIS TREATMENT [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  08.06.2018
Database last updated on 30.03.2026
FormerRequest for examination was made
Status updated on  06.01.2017
FormerThe international publication has been made
Status updated on  31.10.2016
Most recent event   Tooltip27.02.2026New entry: Date of oral proceedings 
Applicant(s)For all designated states
University of Southern California
1150 South Olive Street, Suite 2300
Los Angeles, CA 90015 / US
[2017/06]
Inventor(s)01 / LONGO, Valter D.
8240 Zitola Terrace
Playa del Rey, California 90293 / US
02 / CHOI, In Young
9761 Royal Palm Boulevard
Garden Grove, California 92841 / US
 [2017/06]
Representative(s)GPI Brevets
1330, rue Guillibert de la Lauzière
EuroParc de Pichaury
Bât B2
13856 Aix en Provence Cedex 3 / FR
[N/P]
Former [2017/06]GPI & Associés
EuroParc de Pichaury
Bâtiment B2 - 1er Etage
1330, rue Guillibert de la Lauzière
13856 Aix-en-Provence Cedex 3 / FR
Application number, filing date15774032.502.04.2015
[2017/06]
WO2015US24021
Priority number, dateUS201461974189P02.04.2014         Original published format: US 201461974189 P
[2017/06]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015153850
Date:08.10.2015
Language:EN
[2015/40]
Type: A2 Application without search report 
No.:EP3125904
Date:08.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 08.10.2015 takes the place of the publication of the European patent application.
[2017/06]
Search report(s)International search report - published on:KR08.10.2015
(Supplementary) European search report - dispatched on:EP31.07.2017
ClassificationIPC:A61K31/70, A61K38/00, A61P29/00
[2017/06]
CPC:
A23L33/30 (EP,KR,US); A61K31/70 (KR,RU); A61K38/00 (EP,KR,US);
A61K45/06 (EP,KR,US); A61P21/00 (EP); A61P25/00 (EP);
A61P25/02 (EP); A61P25/18 (EP); A61P25/24 (EP);
A61P25/28 (EP); A61P27/02 (EP); A61P29/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); G01N33/564 (US);
A23V2002/00 (US); G01N2800/285 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/06]
TitleGerman:BEHANDLUNG VON AUTOIMMUNITÄT UND MULTIPLER SKLEROSE[2017/06]
English:AUTOIMMUNITY AND MULTIPLE SCLEROSIS TREATMENT[2017/06]
French:TRAITEMENT DE L'AUTO-IMMUNITÉ ET DE LA SCLÉROSE EN PLAQUES[2017/06]
Entry into regional phase31.10.2016National basic fee paid 
31.10.2016Search fee paid 
31.10.2016Designation fee(s) paid 
31.10.2016Examination fee paid 
Examination procedure31.10.2016Examination requested  [2017/06]
31.10.2016Date on which the examining division has become responsible
17.01.2018Amendment by applicant (claims and/or description)
07.06.2018Despatch of a communication from the examining division (Time limit: M04)
09.08.2018Reply to a communication from the examining division
17.03.2022Despatch of a communication from the examining division (Time limit: M04)
07.07.2022Reply to a communication from the examining division
30.10.2023Despatch of a communication from the examining division (Time limit: M04)
20.02.2024Reply to a communication from the examining division
02.12.2026Date of oral proceedings
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
27.04.2018Renewal fee patent year 04
29.04.2019Renewal fee patent year 05
27.04.2020Renewal fee patent year 06
27.04.2021Renewal fee patent year 07
27.04.2022Renewal fee patent year 08
27.04.2023Renewal fee patent year 09
29.04.2024Renewal fee patent year 10
28.04.2025Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I] WO2006118665  (ACCERA INC et al.) [I] 1-15 * page 5, lines 2-20; page 7, lines 5-24; page 9, lines 7-16; page 1, lines 7-11; example 1; claims 1-20 *
 [I] WO2013028555  (EUROP KETOGENIC WEIGHT LOSS CLINICS LLC et al.) [I] 1-15 * paragraph 34; claims 1-22 *
 [A] EP2353595  (MEAD JOHNSON NUTRITION CO et al.) [A] 1-15 * claims 1-15 *
Examination  OF ET AL: "DIETARY GUIDELINES FOR AMERICANS 2015-2020 (EIGHTH EDITION)", ROOM 509F HHH BLDG, 1 December 2015 (2015-12-01), XP055900502, Retrieved from the Internet [retrieved on 20220311]
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.